Physician profile
James Zubernis
NPI 1609974385
$345.80
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.12 · 2020: $162 · 2021: $69.03 · 2022: $44.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $99.37 | 2020-2022 | |
| Karl Storz Endoscopy-America | $58.32 | 2019 | |
| Ethicon US, LLC | $30.76 | 2020 | |
| Biom'Up France Sas | $28.79 | 2020 | |
| Myovant Sciences INC. | $23.22 | 2021 | |
| Therapeuticsmd, INC. | $22.76 | 2020 | |
| Hologic Sales and Service, LLC | $16.70 | 2020 | |
| Minerva Surgical, INC | $15.31 | 2020 | |
| Novo Nordisk INC | $13.65 | 2022 | |
| Mylan Pharmaceuticals INC. | $13.38 | 2021 | |
| Covidien LP | $11.80 | 2019 | |
| Exeltis, USA INC. | $11.74 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Zubernis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.